| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
N/A |
| Shares
Out: |
61,150,000 |
| Market
Cap: |
6.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$113.49 - $145.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
12,000 |
12,000 |
12,000 |
| Total Buy Value |
$0 |
$1,435,800 |
$1,435,800 |
$1,435,800 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
1 |
1 |
| Total Shares Sold |
8,704 |
9,538 |
24,727 |
196,382 |
| Total Sell Value |
$986,699 |
$1,086,171 |
$3,194,336 |
$28,520,846 |
| Total People Sold |
2 |
4 |
12 |
19 |
| Total Sell Transactions |
3 |
5 |
20 |
73 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Miller Michael Patrick |
EVP, US Commercial |
• – – |
2018-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
28,529 |
|
- |
|
| Miller Michael Patrick |
EVP, US Commercial |
• – – |
2018-02-14 |
4 |
AS |
$139.99 |
$27,998 |
D/D |
(200) |
21,469 |
|
- |
|
| Young Matthew P. |
EVP & CFO |
• – – |
2018-01-16 |
4 |
AS |
$152.16 |
$106,512 |
D/D |
(700) |
38,959 |
|
- |
|
| Miller Michael Patrick |
EVP, US Commercial |
• – – |
2018-01-12 |
4 |
AS |
$148.65 |
$29,730 |
D/D |
(200) |
21,669 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2018-01-12 |
4 |
AS |
$150.00 |
$450,000 |
D/D |
(3,000) |
273,737 |
|
- |
|
| Cox Russell J. |
EVP & COO |
• – – |
2017-12-11 |
4 |
OE |
$8.23 |
$691,676 |
D/D |
50,758 |
102,821 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2017-12-11 |
4 |
AS |
$138.15 |
$1,257,582 |
D/D |
(9,000) |
16,339 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2017-12-11 |
4 |
OE |
$46.83 |
$578,655 |
D/D |
9,000 |
25,339 |
|
- |
|
| Miller Michael Patrick |
EVP, US Commercial |
• – – |
2017-12-11 |
4 |
AS |
$139.15 |
$27,830 |
D/D |
(200) |
21,869 |
|
- |
|
| Mcgill Iain |
SVP, Europe & Rest of World |
• – – |
2017-11-17 |
4 |
S |
$133.42 |
$1,067,358 |
D/D |
(8,000) |
20,383 |
|
- |
|
| Mcgill Iain |
SVP, Europe & Rest of World |
• – – |
2017-11-17 |
4 |
OE |
$46.83 |
$374,640 |
D/D |
8,000 |
28,383 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2017-11-17 |
4 |
AS |
$133.19 |
$46,883 |
D/D |
(352) |
1,365 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2017-10-02 |
4 |
AS |
$150.00 |
$150,000 |
D/D |
(1,000) |
276,664 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2017-09-12 |
4 |
AS |
$153.52 |
$153,520 |
D/D |
(1,000) |
277,664 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2017-08-25 |
4 |
AS |
$148.40 |
$52,088 |
D/D |
(351) |
1,717 |
|
- |
|
| Miller Michael Patrick |
EVP, US Commercial |
• – – |
2017-08-15 |
4 |
AS |
$144.38 |
$28,876 |
D/D |
(200) |
21,996 |
|
- |
|
| Treacy Paul |
SVP, Technical Operations |
• – – |
2017-08-14 |
4 |
S |
$143.30 |
$186,884 |
D/D |
(1,304) |
16,385 |
|
- |
|
| Mcsharry Heather Ann |
Director |
– • – |
2017-08-11 |
4 |
S |
$142.36 |
$102,077 |
D/D |
(717) |
6,724 |
|
- |
|
| Okeefe Kenneth W |
Director |
– • – |
2017-08-11 |
4 |
S |
$142.36 |
$94,248 |
D/D |
(662) |
12,810 |
|
- |
|
| Gray Peter |
Director |
– • – |
2017-08-11 |
4 |
S |
$142.36 |
$102,078 |
D/D |
(717) |
7,402 |
|
- |
|
| Berns Paul L |
Director |
– • – |
2017-08-11 |
4 |
S |
$142.36 |
$94,248 |
D/D |
(662) |
5,937 |
|
- |
|
| Winningham Rick E |
Director |
– • – |
2017-08-11 |
4 |
S |
$142.36 |
$94,248 |
D/D |
(662) |
11,094 |
|
- |
|
| Schnee Elmar |
Director |
– • – |
2017-08-11 |
4 |
S |
$142.36 |
$170,699 |
D/D |
(1,199) |
5,341 |
|
- |
|
| Sohn Catherine A. |
Director |
– • – |
2017-08-11 |
4 |
S |
$142.36 |
$94,248 |
D/D |
(662) |
6,819 |
|
- |
|
| Riedel Norbert G |
Director |
– • – |
2017-08-11 |
4 |
S |
$142.36 |
$94,248 |
D/D |
(662) |
5,656 |
|
- |
|
1250 Records found
|
|
Page 21 of 50 |
|
|
0.37 (0.34%) 
